Cas:1185292-57-2 ethyl 2-(trifluoromethyl)quinoline-4-carboxylate manufacturer & supplier

We serve Chemical Name:ethyl 2-(trifluoromethyl)quinoline-4-carboxylate CAS:1185292-57-2 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

ethyl 2-(trifluoromethyl)quinoline-4-carboxylate

Chemical Name:ethyl 2-(trifluoromethyl)quinoline-4-carboxylate
CAS.NO:1185292-57-2
Synonyms:ethyl 2-(trifluoromethyl)quinoline-4-carboxylate
Molecular Formula:C13H10F3NO2
Molecular Weight:269.21900
HS Code:

Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:39.19000
Exact Mass:269.06600
LogP:3.43030

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like ethyl 2-(trifluoromethyl)quinoline-4-carboxylate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,ethyl 2-(trifluoromethyl)quinoline-4-carboxylate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,ethyl 2-(trifluoromethyl)quinoline-4-carboxylate Use and application,ethyl 2-(trifluoromethyl)quinoline-4-carboxylate technical grade,usp/ep/jp grade.


Related News: With the global industrial division of labor and the change in the business model of multinational pharmaceutical companies, the outsourced market for patented drug substances will further expand. ethyl 2-(trifluoromethyl)quinoline-4-carboxylate manufacturer According to the 2013-2018 New Drug Review Summary report, from 2013 to 2018, new drug applications have shown a year-on-year growth trend. In 2018, domestically produced Class 1 new drugs have declared 225 varieties, the highest in 10 years. ethyl 2-(trifluoromethyl)quinoline-4-carboxylate supplier In addition, a high-standard GMP workshop is under construction and is expected to be put into production within the year. As the capacity bottleneck is broken, the pharmaceutical intermediate business is expected to grow rapidly in the future, providing the company with new growth momentum. ethyl 2-(trifluoromethyl)quinoline-4-carboxylate vendor With the global industrial division of labor and the change in the business model of multinational pharmaceutical companies, the outsourced market for patented drug substances will further expand. ethyl 2-(trifluoromethyl)quinoline-4-carboxylate factory For this study, researchers purchased 231 different cosmetics products in the United States and Canada and tested them for fluorine, Bruton said.